Journal Articles
2020

Clinical Management of Hyperkalemia
B. F. Palmer
J. J. Carrero
D. J. Clegg
G. B. Colbert
M. Emmett

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Nephrology Commons

Recommended Citation
Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, Hain DJ, Lerma E, Onuigbo M, Weir
MR, . Clinical Management of Hyperkalemia. . 2020 Jan 01; ():Article 7437 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/7437. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
B. F. Palmer, J. J. Carrero, D. J. Clegg, G. B. Colbert, M. Emmett, S. Fishbane, D. J. Hain, E. Lerma, M.
Onuigbo, M. R. Weir, and +3 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/7437

REVIEW

Clinical Management of Hyperkalemia
Biff F. Palmer, MD; Juan Jesus Carrero, PharmD, PhD; Deborah J. Clegg, PhD;
Gates B. Colbert, MD; Michael Emmett, MD; Steven Fishbane, MD;
Debra J. Hain, PhD, APRN, AGPCNP-BC; Edgar Lerma, MD;
Macaulay Onuigbo, MD; Anjay Rastogi, MD; Simon D. Roger, MD;
Bruce S. Spinowitz, MD; and Matthew R. Weir, MD
Abstract
Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences. Despite
various guidelines, no universally accepted consensus exists on best practices for hyperkalemia
monitoring, with variations in precise potassium (Kþ) concentration thresholds or for the management of acute or chronic hyperkalemia. Based on the available evidence, this review identiﬁes several
critical issues and unmet needs with regard to the management of hyperkalemia. Real-world studies
are needed for a better understanding of the prevalence of hyperkalemia outside the clinical trial
setting. There is a need to improve effective management of hyperkalemia, including classiﬁcation and
Kþ monitoring, when to reinitiate previously discontinued renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, and when to use oral Kþ-binding agents. Monitoring serum Kþ should be
individualized; however, increased frequency of monitoring should be considered for patients with
chronic kidney disease, diabetes, heart failure, or a history of hyperkalemia and for those receiving
RAASi therapy. Recent clinical studies suggest that the newer Kþ binders (patiromer sorbitex calcium
and sodium zirconium cyclosilicate) may facilitate optimization of RAASi therapy. Enhancing the
knowledge of primary care physicians and internists with respect to the safety proﬁles of these newer
Kþ binders may increase conﬁdence in managing patients with hyperkalemia. Lastly, the availability of
newer Kþ-binding agents requires further study to establish whether stringent dietary Kþ restrictions
are needed in patients receiving Kþ-binder therapy. Individualized monitoring of serum Kþ among
patients with an increased risk of hyperkalemia and the use of newer Kþ-binding agents may allow for
optimization of RAASi therapy and more effective management of hyperkalemia.
ª 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2020;nn(n):1-19

H

yperkalemia, deﬁned as an elevated
serum potassium (Kþ) concentration of greater than 5.0 or greater
than 5.5 mEq/L (mmol/L), is an electrolyte
abnormality with potentially life-threatening
consequences.1 The risk for development of
hyperkalemia is increased in patients with
chronic kidney disease (CKD), diabetes, and
heart failure (HF) and in individuals
receiving renin-angiotensin-aldosterone system inhibitors (RAASis).1-3
Guidelines/consensus statements for hyperkalemia management have been developed.1,2,4-9 However, no universally accepted
consensus exists regarding best practices,
particularly in consideration of newer Kþ

binders and their use in patients with hyperkalemia due to CKD or the adverse effects of
RAASis, a widely used drug class with signiﬁcant cardiorenal beneﬁts.1 Thus, new management guidelines are needed to incorporate
these Kþ binders into hyperkalemia treatment.
This review summarizes the physiology of
hyperkalemia and suggests evidence-based
clinical considerations that may provide improvements in care and outcomes in patients
with an increased hyperkalemia risk.
METHODS
We conducted a literature search of the
PubMed database for articles published between January 1, 2000, and October 14,
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An unmet need exists for new hyperkalemia management
guidelines that effectively incorporate classiﬁcation and monitoring for hyperkalemia, optimization of renin-angiotensinaldosterone system inhibitor (RAASi) therapy, and use of the
newer potassium (Kþ) binders.
Treatment gaps exist between guideline recommendations and
RAASi use in clinical practice among patients with an increased
risk of hyperkalemia; if discontinued, RAASi therapy should be
reinitiated after acute hyperkalemia has resolved.
The frequency of Kþ monitoring should be individualized on the
basis of patient comorbidities and medications (eg, RAASi), particularly in patients at high risk for development of hyperkalemia.
Patients with chronic hyperkalemia may beneﬁt from long-term
Kþ-binding therapy, initiated at the recommended dose and
titrated according to serum Kþ levels.
Use of the newer Kþ binders may enable the optimization of
RAASi therapy in more patients with hyperkalemia.

2019. Search terms included chronic kidney
disease, diabetes, heart failure, hyperkalaemia,
hyperkalemia, patiromer, potassium, reninangiotensin-aldosterone system inhibitor, sodium polystyrene sulfonate, SPS, sodium zirconium cyclosilicate, SZC, and ZS9. The results
of this literature search were reviewed by researchers, epidemiologists, clinicians, dietitians, and trialists in the ﬁeld of hyperkalemia.
POTASSIUM HOMEOSTASIS AND
HYPERKALEMIA
Potassium homeostasis is largely maintained by
the kidneys, although the gastrointestinal tract
and other systems are also involved to a lesser
extent (Figure 1).7,10 Hyperkalemia has depolarizing effects on the heart,10 causing shortened
action potentials and increasing the risk of arrhythmias.11 Hyperkalemia causes neuromuscular symptoms,10,12 metabolic acidosis, and
suppression of ammoniagenesis.13
The risk of mortality, cardiovascular
morbidity, progression of CKD, and hospitalization is increased in patients with hyperkalemia, especially those with CKD, HF, and
2
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diabetes.14,15 A U-shaped curve exists between
serum Kþ and mortality, with both hyperkalemia and hypokalemia associated with adverse
clinical outcomes (Figure 2).14 However, the
exact Kþ concentration that clinicians should
consider to be life-threatening remains controversial. The risk of hyperkalemia and the
optimal range for serum Kþ concentrations
vary according to individual patient comorbidities, such as CKD, HF, or diabetes. For
example, a patient with atrioventricular heart
block may experience worsening of cardiac
symptoms at a lower Kþ concentration than
another patient without the same condition.16
The rate of increase in Kþ concentrations must
also be considered, as a rapid increase in serum
Kþ is more likely to result in cardiac abnormalities than a slow steady rise over several
months.17 In patients with CKD, compensatory mechanisms may result in tolerance to
elevated circulating Kþ, and several studies
have suggested that hyperkalemia is a less
threatening condition in CKD.15,18-22 A retrospective study found a stronger association between hyperkalemia (Kþ 5.5 mEq/L) and
1-day mortality among inpatients and outpatients with normal kidney function than in
those with CKD (estimated glomerular ﬁltration rate [eGFR] <60 mL/min per 1.73
m2).18 A U-shaped correlation was found
between serum Kþ and overall mortality
risk in patients with nonedialysis-dependent
CKD,19 and in a study of consecutive hospitalizations for severe hyperkalemia, a graded
decrease in the risk of mortality was observed
as CKD stage worsened.20 In a cohort study
of patients with stage 3 to 5 CKD, the risk of
preeend-stage renal disease (ESRD) mortality
was lower when serum Kþ concentrations
were 4.0 to 5.5 mEq/L compared with 4.0
mEq/L or less and was not increased with
serum Kþ levels of 5.5 mEq/L or greater.21
Lastly, in a large cohort study evaluating the
potential reduction in mortality risk from
hyperkalemia with worsening CKD in more
than 800,000 individuals, an evaluation of
90-day mortality risk in relation to Kþ concentrations revealed that the observed optimal Kþ
range was broader toward higher Kþ concentration in patients with stage 4 to 5 CKD
XXX 2020;nn(n):1-19
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(optimal range, 3.3 to 5.5 mEq/L) than in those
with stage 1 to 2 CKD (optimal range, 3.5 to
5.0 mEq/L).15
The mechanisms underlying this possible
increase in tolerance to hyperkalemia among
patients with advanced CKD are not fully understood. It has been suggested that patients
with CKD adapt to elevated Kþ concentrations through modiﬁcations in gastrointestinal Kþ secretions10,23 which may favor
intracellular Kþ storage,24 or by increasing
insulin-mediated intracellular Kþ uptake in
splanchnic and peripheral muscle tissues.25
However, it is unknown whether these adaptations to increased serum Kþ exist in other
cells (eg, cardiomyocytes). Potassium channels in the myocardium are known to be sensitive to shifts in endogenous factors and may
change in number or functioning in response
to structural26,27 and environmental28 alteration. Therefore, future studies should investigate whether these changes in myocardial
Kþ channels may explain the observed reductions in the relative risk of death from hyperkalemia in patients with advanced CKD. In
addition, given the relationship between
serum Kþ, acidosis, and calcium/magnesium
concentrations,29 it would be interesting to
examine whether metabolic acidosis affects
the association between serum Kþ and mortality risk in patients with CKD.
EPIDEMIOLOGY OF HYPERKALEMIA
Hyperkalemia Incidence
Hyperkalemia is rare in the general population.7 However, because it is a transient condition, no prospective studies monitoring
intraindividual serum Kþ concentrations have
been conducted, and therefore, the exact incidence of hyperkalemia in the general population is unclear. Different Kþ thresholds also
affect the reported incidence of hyperkalemia.
Among hospitalized patients, hyperkalemia
incidence has been reported as 3.5% (>5.5
mEq/L) in Canada16 and 4.9% (>5.0 mEq/L)
in Ireland.17 However, the likelihood of detecting hyperkalemia depends on the frequency of
Kþ monitoring. Two studies of inpatients and/
or outpatients undergoing Kþ testing over 3
years, one in Sweden30 and another in the
Mayo Clin Proc. n XXX 2020;nn(n):1-19
www.mayoclinicproceedings.org
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United States,31 observed higher rates of hyperkalemia (7%30 and 11% [>5.0 mEq/L] and 2%
[>5.5 mEq/L],31 respectively). The worldwide
incidence of hyperkalemia could be underestimated because of the lack of routine Kþ monitoring even in some high-risk patient
populations. Therefore, further epidemiological research in real-world populations is
needed to more accurately estimate hyperkalemia incidence, which may be higher than
observed in clinical trials because of the lack
of consistent Kþ monitoring and the lack of a
standardized hyperkalemia deﬁnition (eg,
serum Kþ >5.0, >5.5, or >6.0 mEq/L).
Risk Factors
Certain patient populations have an increased
risk of hyperkalemia-associated morbidity and
mortality, including patients with advanced
stages of CKD, HF, resistant hypertension, diabetes, myocardial infarction (MI), and/or combinations of these conditions.14,32,33 Additional
risk factors include RAASi usage, advanced
age,2 and drugs such as heparin, b-blockers,
nonsteroidal anti-inﬂammatory drugs, calcineurin inhibitors, trimethoprim, pentamidine,
and Kþ-sparing diuretics.10,34 The risk of
hyperkalemia progressively increases as eGFR
decreases.15 Because chronic loss of kidney
function is associated with an adaptive
response in the remaining functional nephrons,
allowing for an increase in fractional Kþ excretion and maintenance of serum Kþ levels of less
than 5.5 mEq/L, the risk of hyperkalemia is
generally increased once the eGFR is less than
15 mL/min per 1.73 m2.35 Furthermore, patients receiving RAASi therapy who have an
eGFR of less than 60 mL/min per 1.73 m2
have an elevated hyperkalemia risk, which progressively increases as eGFR decreases.3,36 In
patients with CKD and/or chronic HF receiving
RAASi, risk factors for repeated hyperkalemia
within 6 months of the ﬁrst event include moderate to severe initial hyperkalemia (5.6
mEq/L), low eGFR (<45 mL/min per 1.73
m2), diabetes, and spironolactone use.37
Hyperkalemia risk is slightly higher in
men than in women after initiation of RAASi
therapy3 and differs among racial groups, in
whom ethnicity, diet, and socioeconomic factors may contribute.38 These factors currently
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FIGURE 1. Regulation of potassium (Kþ) homeostasis. Absorbed Kþ is largely redistributed from the blood to the intracellular space
by active transport (Naþ/Kþ-ATPase), which is stimulated by insulin and catecholamines. In individuals with normal kidney function, Kþ
is ﬁltered through the glomerulus and reabsorbed in the proximal tubule and loop of Henle; less than 10% of ﬁltered Kþ reaches the
distal nephron. Potassium excretion in the distal nephron and collecting duct is stimulated by aldosterone, increased urine ﬂow, and
increased delivery of sodium to the distal nephron. Increased Kþ intake may also promote renal excretion via enteric sensing and
stimulation of aldosterone release from the adrenal gland. Excess extracellular Kþ is usually managed by increased renal excretion of
Kþ; however, impaired kidney function can cause dysregulation of Kþ homeostasis and increase the risk of hyperkalemia.
GI ¼ gastrointestinal; Naþ/Kþ-ATPase ¼ sodium-potassium pump.

do not impact hyperkalemia management;
however, the potentially additive effects of
these differences may increase hyperkalemia
risk.
A low-Kþ diet is recommended in patients
with advanced-stage CKD to reduce hyperkalemia risk39; however, a recent Kidney Disease:
Improving Global Outcomes (KDIGO) conference found that direct evidence supporting a
link between dietary Kþ intake and serum
Kþ concentrations is limited and that interventional trials are needed to determine optimal
recommendations for dietary Kþ in patients
with CKD.40 A low-Kþ diet is difﬁcult for patients to adhere to, particularly those who
may have additional dietary restrictions due
to diabetes and reduced sodium intake for
CKD or HF. Furthermore, evidence indicates
that a Kþ-rich diet has multiple health beneﬁts
4
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including blood pressure reductions and
reduced risks of CKD progression, cardiovascular disease, and stroke.41 Restriction of dietary Kþ as a general approach to preventing
hyperkalemia may therefore deprive patients
of these beneﬁts.40
RAASi TherapydBeneﬁts and Hyperkalemia Risk
Renin-angiotensin-aldosterone system inhibitors are recommended for patients with hypertension,42 HF,43,44 stable coronary artery
disease,45 CKD, diabetic kidney disease
(DKD),46 and diabetes.47,48 They improve
survival in patients with CKD,49 HF,50,51
and post-MI status52 and also provide kidney
beneﬁts in patients with non-DKD53 and
DKD.54,55 Many patients who would otherwise beneﬁt from RAASis either do not receive
XXX 2020;nn(n):1-19
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these medications, receive suboptimal doses,
or discontinue therapy because of the associated increased risk of recurrent hyperkalemia.1 Treatment gaps exist between
guideline recommendations and RAASi use
in clinical practice in patients with increased
hyperkalemia risk.36,56,57 Compared with
those for maximum RAASi dosing, mortality
rates are higher with suboptimal dosing
among patients with CKD, diabetes or HF
and are highest among patients who discontinue RAASis.57 In one study, 74% of patients
who discontinued mineralocorticoid receptor
antagonists (MRAs) because of hyperkalemia
did not reinitiate therapy during the subsequent year.36 Many patients who have had
acute MI are not prescribed MRAs at hospital
discharge because of hyperkalemia risk.56
Additionally, patients with HF are often prescribed subtherapeutic MRA doses despite
guideline recommendations.58
Although hyperkalemia represents a significant barrier to effective use of RAASis,1,59,60
RAASi therapy is associated with improved survival in patients with HF, particularly in those
at risk for hyperkalemia.61,62 Despite a lack of
randomized controlled trial data to document
improved clinical outcomes with correction of
hyperkalemia and reinitiation of RAASi therapy
in patients with an increased hyperkalemia
risk, there is an increasing body of real-world
evidence of increased morbidity and mortality
among patients with CKD, HF, or diabetes
who receive suboptimal or no RAASi therapy
because of hyperkalemia.63-65 For example, in
a cohort study of patients who experienced a
decline in eGFR to less than 30 mL/min per
1.73 m2 while receiving RAASi therapy, discontinuation of RAASi therapy was associated with
a higher risk of mortality or major adverse cardiovascular events than continuation of RAASis.63 In addition, a recent consensus report9
and a position paper66 suggest that treatment
with the newer Kþ binders (discussed subsequently) may allow for optimization of RAASi
therapy in patients with HF. Therefore,
maximum RAASi therapy, as tolerated, should
be considered when RAASis are indicated.
Hyperkalemia should be treated if it develops,
and reinitiation of RAASis (if discontinued)
should be considered after resolution of acute
Mayo Clin Proc. n XXX 2020;nn(n):1-19
www.mayoclinicproceedings.org

n
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FIGURE 2. The risk of hypokalemia- or hyperkalemia-associated mortality
(a) in patients with chronic kidney disease (CKD) and other comorbidities
over 18 months. DM ¼ diabetes mellitus; HF ¼ heart failure. From Am J
Nephrol,14 with permission.

hyperkalemia. Other potential risk factors for
hyperkalemia should be identiﬁed and
removed, whenever possible, and patients
should be monitored closely, with reassessment of Kþ concentrations within 1 week.
HYPERKALEMIA MANAGEMENT
Management of hyperkalemia occurs across a
continuum ranging from urgent to short-term
treatment and then long-term treatment
and involves both inpatient and outpatient
settings. Different management strategies
are utilized in patients with acute vs chronic
hyperkalemia (Figure 3).
Classiﬁcation of Hyperkalemia
Although the precise Kþ concentration thresholds for mild, moderate, and severe hyperkalemia vary among current guidelines,1,4-6 a serum
Kþ level of 5.5 mEq/L or greater is widely
accepted as the threshold for hyperkalemia.6
Hyperkalemia-associated adverse outcomes
may extend beyond hyperkalemia thresholds
(serum Kþ >5.0 or >5.5 mEq/L) and include
high “normal” Kþ concentrations in patients
with acute or chronic HF,32,67 hypertension,33
or CKD.15 When deciding how to treat hyperkalemic episodes, it may be useful to focus on
hyperkalemia with clinical impact, as well as
rapid ﬂuctuations in serum Kþ, rather than
rigid and somewhat arbitrary serum Kþ
thresholds.

https://doi.org/10.1016/j.mayocp.2020.06.014
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Hyperkalemia

Acute

Monitor:
• K+ trajectory
• ECG changes
• Other symptoms

IV sodium
bicarbonatea

IV insulin/glucose
(10 U + 50 mL dextrose)

Manage RAASi therapy
(reinitiate and titrate to optimal dose after
serum K+ stabilizes)

Nebulized salbutamol
(20 mg in 4 mL)

Effective diuretic therapy
(loop diuretics with eGFR <30 mL/min)

Diureticsb

patients with metabolic acidosis
patients with hypervolemia (nonoliguric)
cIn patients with oliguria or ESRD
bIn

Dietary K+ counseling
(avoid salt substitutes)

IV calcium
(10 mL of 10%)

Consider K+ binders
aIn

Chronic

Hemodialysisc

Monitor:
• Serum K+ ¾2 times/year
• Comorbidities
• Medications (OTC NSAIDs
and herbal supplements)
• Exclude pseudohyperkalemia
Educate:
• Health care professionals
• Patients
Multidisciplinary care:
• Dietitian input
• Pharmacist input

Oral sodium bicarbonatea

Consider K+ binders
(may facilitate RAASi dose optimization)
Stabilize myocardial cell membrane
K+ redistribution into intracellular space
Total body K+ elimination
Reduction of K+ intake
Identification/removal of medications that inhibit renal K+ excretion

FIGURE 3. Treatment options for the management of acute and chronic hyperkalemia. In patients with acute hyperkalemia, intravenous
(IV) calcium reduces membrane excitation in cardiac tissue within 1 to 3 minutes, while insulin and b-agonists redistribute potassium (Kþ)
to the intracellular space (30 to 60 minutes) but do not reduce total body Kþ. b-Agonists have a short duration of effect (2 to 4 hours),
and glucose must be administered with insulin to prevent hypoglycemia. Sodium bicarbonate use, which promotes Kþ elimination
through increased urinary Kþ excretion, is limited to patients with metabolic acidosis, and effective diuretic therapy depends on residual
kidney function. Hemodialysis increases total Kþ elimination and may be used for resistant acute hyperkalemia. ECG ¼ electrocardiography; eGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs;
OTC ¼ over-the-counter; RAASi ¼ renin-angiotensin-aldosterone system inhibition.

Potassium concentration thresholds for
the classiﬁcation of mild, moderate, and severe
hyperkalemia are useful; however, patient
risk- and clinical impact-based classiﬁcation
may also guide clinical intervention. Clinicians
should consider using individualized serum
Kþ concentration thresholds that take into account patient comorbidities and “normal” Kþ
concentration ranges, as well as the rate or degree of change in serum Kþ levels over time,
which enables proactive or preventive interventions and is a useful clinical variable for
hyperkalemia management.
6
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Frequency of Kþ Monitoring
The use of serum or plasma for determination
of Kþ concentrations affects laboratory results.
Plasma Kþ concentrations are usually 0.1- to
0.4-mEq/L lower than serum levels,7 which is
caused by the release of Kþ from platelets during coagulation.68 The methods used for Kþ
determination are not standardized, with
wide variations in reference ranges.7 Complications such as pseudohyperkalemia (resulting from repeated ﬁst clenching and poor
phlebotomy techniques), hemolysis, slow
specimen processing, and other factors7,10,69
XXX 2020;nn(n):1-19

n
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need to be assessed prior to hyperkalemia
treatment. The timing of sample collection
may inﬂuence Kþ results because of the circadian rhythm of Kþ homeostasis.7
Clinical guidelines recommend Kþ measurement in at-risk patients prior to initiation of drugs that inﬂuence hyperkalemia
risk and periodically thereafter.4,46,70,71 For
example, the 2012 KDIGO guidelines advocate serum Kþ measurement within 1 week
of starting or dose escalation of RAASis in
patients with CKD.46 Repetitive consecutive
measurements facilitate determination of
whether hyperkalemia is a chronic or transient event5; however, there is no consensus
on the number of tests required to document
chronic hyperkalemia risk.59 Potassium
monitoring frequency should vary depending on patient comorbidities (eg, diabetes,
HF, CKD stage, and the need for dialysis)
and medications (eg, RAASi therapy).
Individualized Kþ monitoring frequency
based on the presence of comorbidities and
medications should be considered, with
more frequent monitoring in patients with
increased hyperkalemia risk (eg, those with
CKD, diabetes, HF, or a history of hyperkalemia and those taking RAASis). In particular, serum Kþ concentrations should be
assessed 7 to 10 days after starting RAASi
therapy and increasing RAASi doses.
Acute Hyperkalemia
Acute hyperkalemia is deﬁned as a serum Kþ
concentration exceeding the upper limit of
normal that is not known to be chronic.40 Management of acute hyperkalemia depends on the
magnitude or severity of the increase in Kþ concentration, especially when combined with
marked electrocardiographic (ECG) changes
and severe muscle weakness.4,40 The most
commonly observed changes in ECG are
peaked T waves and prolonged QRS complexes.40 However, as noted in the observational REVEAL-ED (Real World Evidence
for Treatment of Hyperkalemia in the
Emergency Department) study of emergency
department patients who presented with Kþ
concentrations of 5.5 mEq/L or greater,72 the
symptoms of hyperkalemia can be nonspeciﬁc,
and although recommended for determining
Mayo Clin Proc. n XXX 2020;nn(n):1-19
www.mayoclinicproceedings.org
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the clinical relevance of elevated serum Kþ,
ECG ﬁndings can be highly variable and not
as sensitive as a laboratory test in predicting
hyperkalemia or its associated complications.
A deep learning model that may allow for
noninvasive screening for hyperkalemia using
ECG is currently being developed73; however,
this tool is not yet available for use in routine
clinical practice. Therefore, Kþ measurements
should be conducted on the basis of the patient’s risk factors rather than clinical symptoms (Figure 3).
The goal of managing acute hyperkalemia is to prevent or minimize electrophysiologic effects on the heart to reduce the
immediate risk of arrhythmias.2,5,7 Treatment options for acute hyperkalemia include
intravenous calcium gluconate, insulin/
glucose, inhaled b-agonists (eg, salbutamol),
intravenous sodium bicarbonate, and hemodialysis (Figure 3). Intravenous calcium gluconate administration rapidly reduces the
membrane excitatory effects of Kþ on cardiac tissue within 1 to 3 minutes, thereby
minimizing the potential for cardiac
arrhythmia, but only minimally reduces
serum Kþ concentrations.2,74 If no effect is
observed within 5 to 10 minutes, another
dose of calcium gluconate may be given.75
Intravenous insulin (plus glucose) and
inhaled b-agonists act within 30 minutes to
promote redistribution of serum Kþ into
the intracellular space but do not change total body Kþ levels.74 Short-term treatment
with oral sodium bicarbonate may be used
to promote Kþ elimination through
increased urinary Kþ excretion in patients
with concurrent metabolic acidosis,2 countering the release of Kþ into the blood that
is caused by metabolic acidosis by decreasing
blood acidity and promoting Kþ excretion
through increased distal sodium delivery.76
Dialysis increases Kþ elimination from the
body and may be used as an adjunctive therapy in acute hyperkalemia after instituting
other approaches.2
Several deﬁciencies associated with current
management of acute hyperkalemia were highlighted by the REVEAL-ED study, including a
lack of standard, universally accepted treatment protocols or algorithms for managing

https://doi.org/10.1016/j.mayocp.2020.06.014
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hyperkalemia in the emergency department.72
The study documented the use of different
treatments, alone or in combination, depending on the institution and initial blood Kþ concentration, including intravenous calcium,
inhaled b2-agonists, oral sodium polystyrene
sulfonate (SPS), intravenous sodium bicarbonate, dialysis, and intravenous diuretics. Insulin/
glucose (alone or in combination with other
therapy) was the most commonly utilized
option (64% of patients) within the ﬁrst 4
hours,72 whereas the treatment option most
likely to achieve normokalemia within 4 hours
was dialysis.
Chronic Hyperkalemia
Chronic hyperkalemia is deﬁned as recurrent
episodes of elevated serum Kþ concentrations
that require ongoing maintenance therapy;
however, based on the recent KDIGO report,40
there is no consensus on the frequency,
severity, or duration of these episodes that describes chronicity. In general, chronic hyperkalemia is more likely to be identiﬁed in
individuals who have more frequent testing
and is often asymptomatic.40 Current recommendations regarding the management of
chronic hyperkalemia (long-term elevated
serum Kþ) include the use of loop or thiazide
diuretics, modiﬁcation of RAASi dose, and
removal of other hyperkalemia-causing medications (Figure 3).2,34,40 Diuretics promote
urinary excretion of Kþ in patients with CKD
or DKD by stimulating the ﬂow and delivery
of Kþ to the renal collecting ducts.76 Fludrocortisone can also increase Kþ excretion but
is associated with an increased risk of ﬂuid
retention, hypertension, and vascular
injury.2,11
These long-term treatment options have
limitations.2 Despite the beneﬁcial effects of diuretics on volume status and blood pressure in
patients with CKD or HF, these agents may increase the risk of gout, volume depletion,
decreased distal nephron ﬂow, worsening kidney function, and reduced Kþ excretion, and
their effectiveness in managing hyperkalemia
relies on residual kidney function. Discontinuation or dose reduction of RAASi therapy may
lead to adverse cardiorenal outcomes, and current guidelines differ with regard to
8
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recommendations on when to reinitiate RAASi
(Table 1).4,44,46,71 Recently US Food and Drug
Administrationeapproved Kþ-binding agents
may provide beneﬁts for the management of
chronic hyperkalemia while avoiding these
limitations. Educational initiatives on the
safety and efﬁcacy of the newer Kþ binders
are needed for primary care physicians and internists to increase their knowledge of hyperkalemia management, especially in regions
where specialist services may not be readily
available. A team approach for chronic hyperkalemia management is optimal, which may
include specialists (eg, cardiologists, nephrologists), primary care physicians, nurses, pharmacists, social workers, or dietitians.
Potassium Binders
All Kþ binders used for hyperkalemia management are nonabsorbed and consist of a counterion that is exchanged for Kþ, facilitating
the elimination of bound Kþ in feces.77-79 Until
recently, SPS (Kayexalate)78,80 was the only
Kþ binder available for hyperkalemia management and may continue to be the only agent
available in parts of the world. However, 2
other Kþ binders, patiromer sorbitex calcium
(Veltassa)77 and sodium zirconium cyclosilicate (SZC; Lokelma [formerly ZS-9]),79 are
now approved in the United States and the European Union. The characteristics of these 3
Kþ-binding agents are summarized in
Table 2.12,59,60,79-81 The efﬁcacy of patiromer
and SZC has been documented in clinical trials, whereas clinical data for SPS is limited (discussed subsequently and summarized in
Table 3).82-94 The newer Kþ-binding agents
are also more palatable than SPS, facilitating
adherence and efﬁcacy and potentially leading
to improved outcomes.89,90,92,95 The National
Institute for Health and Care Excellence has
recently provided recommendations regarding
SZC and patiromer use for the treatment of
acute life-threatening hyperkalemia, stating
that these agents may be considered for use
in conjunction with standard care.95,96
The initiation of newer Kþ-binding agents
should be considered in patients with chronic
hyperkalemia despite optimized diuretic therapy and correction of metabolic acidosis. After
starting therapy at the recommended dose, Kþ
XXX 2020;nn(n):1-19

n
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TABLE 1. Summary of Guideline Recommendations for RAASi Therapya
Serum Kþ (mEq/L)

Society

Recommendations for RAASi therapy

American College of Cardiology/American Heart
Association/ Heart Failure Society of America44

>5.0

Use ACEis and ARBs with caution
MRAs are not recommended

Canadian Cardiovascular Society4

Mild HK (Kþ 5.0-5.5)

RAASi not usually stopped
If RAASi therapy is stopped, reinitiate therapy once any
concurrent condition contributing to changes in Kþ is
under control AND serum Kþ has decreased to <5.0
mEq/L or to within patient’s usual range (whichever is
higher)

Moderate (Kþ 5.6-5.9) or
severe (Kþ >5.9) HK

Reinitiate RAASi therapy once any concurrent condition
contributing to changes in Kþ is under control AND
serum Kþ has decreased to <5.0 mEq/L or to within
patient’s usual range (whichever is higher)
Reintroduce RAASi agents one at a time with monitoring
of kidney function and electrolytes

4.5-5.0b

If not taking maximum-tolerated guideline-recommended
dose, initiate/up-titrate RAASi therapy and closely
monitor Kþ; start Kþ-lowering therapy if Kþ increases to
>5.0 mEq/L

>5.0 to 6.5

If receiving maximum-tolerated guideline-recommended
RAASi dose, initiate Kþ-lowering therapy; closely
monitor Kþ and continue Kþ-lowering therapy unless
another treatable etiology for hyperkalemia is identiﬁed

European Society of Cardiology1

If not taking maximum-tolerated guideline-recommended
RAASi dose, start Kþ-lowering therapy and titrate
RAASi when Kþ is <5.0 mEq/L; closely monitor Kþ and
maintain Kþ-lowering therapy unless another etiology
for hyperkalemia is identiﬁed
>6.5

Discontinue or reduce RAASi therapy; Kþ-lowering
therapy may be started as soon as Kþ is >5.0 mEq/L;
closely monitor serum Kþ

Kidney Disease: Improving Global Outcomes46

NS

Assess GFR and measure serum Kþ within 1 week of
starting RAASi or following any dose escalation

National Institute for Health and Care Excellence71

>5.0
6.0

Do not initiate RAASi therapy in patients with CKD
Discontinue RAASi therapy once other drugs known to
increase the risk of hyperkalemia have been stopped

ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CKD ¼ chronic kidney disease; GFR ¼ glomerular ﬁltration rate; HK¼ hyperkalemia;
Kþ ¼ potassium; MRA ¼ mineralocorticoid receptor antagonist; NS ¼ not speciﬁed; RAASi ¼ renin-angiotensin-aldosterone system inhibitor.
b
Serum or plasma Kþ.
a

binders should be titrated for optimization of
serum Kþ concentration, with individualized
monitoring of serum or plasma Kþ. Longterm Kþ-binder therapy may be considered
in patients with chronic hyperkalemia. The
use of one of the newer Kþ-binding agents
(patiromer or SZC) may allow for the continuation and optimization of RAASi therapy in patients with hyperkalemia. Consideration of the
costs of patiromer or SZC may inﬂuence their
use in clinical practice for some patients.
Mayo Clin Proc. n XXX 2020;nn(n):1-19
www.mayoclinicproceedings.org

n

Although such data are limited, costeffectiveness analysis from the US payer
perspective found that the beneﬁts of adding
patiromer to treatment in patients with HF
and hyperkalemia outweighed the incremental
total costs, with lower hospitalization costs,
improved survival, and increased quality of
life.97
Sodium Polystyrene Sulfonate. Sodium
polystyrene sulfonate is a polymeric cation-
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TABLE 2. Selected Characteristics of Kþ-Binding Agents for Hyperkalemia
Characteristic

SPS

Patiromer

SZC

Approval date

1958

US, 2015; EU, 2017

US, 2018; EU, 2018

Mechanism of action

Kþ binding in exchange for Naþ in
GI tract ([ fecal excretion)

Kþ binding in exchange for Ca2þ in
GI tract ([ fecal excretion)

Kþ binding in exchange for Hþ and
Naþ in GI tract ([ fecal
excretion)

Site of action

Colon

Colon

Small and large intestines

Selectivity for Kþ

Nonselective; also binds Ca2þ and
Mg2þ

Nonselective; also binds Naþ and
Mg2þ

Highly selective; also binds NH4þ

Onset of action

Variable; several hours

7h

1h

Naþ content

1500 mg per 15-mg dose

None

400 mg per 5-g dose

Ca2þ content

None

1.6 g per 8.4-g dose

None

Sorbitol content

20,000 mg per 15-g dose

4000 mg per 8.4-g dose

No sorbitol content

Dosing

15 g 1-4 times (oral); 30-50 g
1-2 times (rectal)

8.4 g QD (oral), titrate up to 16.8 g
or 25.2 g QD

10 g TID (oral) for initial correction
of hyperkalemia (for 48 h),
then 5 g QOD to 15 g QD for
maintenance

Serious AEs

Cases of fatal GI injury reported

None reported

None reported

Most common AEs

GI disorders (constipation,
diarrhea, nausea, vomiting,
gastric irritation),
hypomagnesemia, hypokalemia,
hypocalcemia, systemic alkalosis

GI disorders (abdominal
discomfort, constipation,
diarrhea, nausea, ﬂatulence),
hypomagnesemia

GI disorders (constipation,
diarrhea, nausea, vomiting), mild
to moderate edema

AE ¼ adverse event; Ca2þ ¼ calcium; EU ¼ European Union; GI ¼ gastrointestinal; Hþ ¼ hydrogen ion; Kþ ¼ potassium; Mg2þ ¼ magnesium; Naþ ¼ sodium; NH4þ ¼
ammonium; QD ¼ once daily; QOD ¼ every other day; SPS ¼ sodium polystyrene sulfonate; SZC ¼ sodium zirconium cyclosilicate; TID ¼ three times daily; US ¼ United
States; [ ¼ increased.
Data from references 12, 59, 60, and 79 to 81.

exchange resin that binds Kþ ions in
exchange for sodium ions in the distal colon.12,78 It is nonselective for Kþ, with
afﬁnity for calcium and magnesium ions.
Sodium polystyrene sulfonate may be
administered either orally or rectally,78
although the oral suspension has poor
palatability.98 With only one small randomized, double-blind, 7-day trial, clinical
studies supporting its long-term use in patients with hyperkalemia are lacking
(Table 3).82 Its short-term efﬁcacy is also
inconsistent,2 and the onset of action is
variable (hours to days).78 Its use varies
widely among countries, ranging from 42%
of patients in France to less than 1% in the
United Kingdom, Spain, and Japan.99
Sodium polystyrene sulfonate has been
associated with adverse events (AEs),
including intestinal ischemia and colonic necrosis,100,101 a doubling in the risk of hospitalization for serious gastrointestinal AEs,102
and a reported overall mortality rate of 33%
10
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for patients with serious gastrointestinal
injury.103 However, although cohort studies
have reported a higher relative risk of gastrointestinal AEs with SPS use, the incidence of
events with SPS was rare (16 or 23 events
per 1000 person-years).101,102 Because of its
potential to cause constipation, SPS was often
previously coadministered with the laxative
sorbitol.12 However, in 2009, the US Food
and Drug Administration added a warning label to SPS regarding the concomitant use of
sorbitol and the associated risk of colonic necrosis and other serious gastrointestinal AEs
(bleeding, ischemic colitis, and perforation).104 Coadministration of SPS with sorbitol is currently not recommended,78 although
gastrointestinal injury has been reported in
patients receiving SPS without sorbitol.101-103
The nonselective binding properties of
SPS may also lead to hypocalcemia and hypomagnesemia,12 and because orally administered SPS potentially binds to other oral
medications, their administration should be
XXX 2020;nn(n):1-19

n
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TABLE 3. Summary of Key Clinical Studies of Kþ-Binding Agentsa
Study name; design (duration)

Patient population

Study treatment

Primary efﬁcacy outcomes

SPS
Outpatients with CKD and
mild hyperkalemia (Kþ
5.0-5.9 mEq/L); N¼33

SPS 30 g or placebo QD

Mean change in serum Kþ:
1.25 mEq/L with SPS
0.21 mEq/L with placebo
Mean difference (95% CI) vs placebo:
1.04 mEq/L (1.37 to 0.71
mEq/L); P<.001

Phase 4, randomized, openlabel, single-blind (10 h)83

Emergency department
patients with ESRD and
serum Kþ 6.0 mEq/L;
N¼43

Single dose of patiromer
25.2 g þ SOC or SOC alone

Adjusted mean serum Kþ at 6 h:
5.81 mEq/L with patiromer þ SOC
6.32 mEq/L with SOC alone; P¼.155
vs SOC alone
Adjusted mean serum Kþ at 2 h:
5.90 mEq/L with patiromer þ SOC
6.51 mEq/L with SOC alone; P¼.009
vs SOC alone

PEARL-HF; phase 2,
randomized, double-blind,
placebo-controlled (28 d)84

Patients with chronic HF
with (1) history of
hyperkalemia leading to
RAASi and/or b-blocker
withdrawal or (2) CKD;
N¼105

Patiromer 15 g or placebo BID
(þ spironolactone 25 mg/db)

LS mean change in serum Kþ:
0.22 mEq/L with patiromer
þ0.23 mEq/L with placebo
LS mean difference vs placebo:
0.45 mEq/L; P<.001

AMETHYST-DN; phase 2,
randomized, open-label
(28 d)85

Outpatients with DKD and
mild (Kþ 5.0-5.5 mEq/L)
or moderate (Kþ 5.5-6.0
mEq/L) hyperkalemia;
N¼306

Mild hyperkalemia: patiromer 4.2,
8.4, or 12.6 g BIDc

Mild hyperkalemia:
LS mean change in serum Kþ:
0.35 mEq/L with patiromer 4.2 g
0.51 mEq/L with patiromer 8.4 g
0.55 mEq/L with patiromer 12.6 g

Moderate hyperkalemia:
patiromer 8.4, 12.6, or 16.8 g
BIDc

Moderate hyperkalemia:
LS mean change in serum Kþ:
0.87 mEq/L with patiromer 8.4 g
0.97 mEq/L with patiromer 12.6 g
0.92 mEq/L with patiromer 16.8 g

Phase 4, randomized,
double-blind, placebocontrolled (7 d)82

Patiromer

AMBER; phase 2,
randomized, double-blind,
placebo-controlled
(12 wk)86

Patients with CKD, Kþ 4.35.1 mEq/L, and resistant
hypertension; N¼295

Patiromer 8.4 g or placebo QD
(þ open-label spironolactone
25 mg/dd)

Patients remaining on spironolactone:
86% with patiromer
66% with placebo
Difference vs placebo:
19.5%; P<.0001
More patients in placebo vs patiromer
with serum
Kþ 5.5 mEq/L:
P<.001

OPAL-HK; phase 3, 2 stages:
(1) treatment, single-group,
single-blind (4 wk) and (2)
with-drawal, randomized,
single-blind, placebocontrolled (8 wk)87

Patients with CKD on
RAASi therapy with mild
(Kþ 5.1-5.5 mEq/L) or
moderate to severe (Kþ
5.5-6.5 mEq/L)
hyperkalemia; N¼237

Treatment stage: patiromer 4.2 g
(mild hyper-kalemia) or 8.4 g
(moderate to severe hyperkalemia) BID

Treatment stage:
Mean change in serum Kþ at wk 4:
Overall: 1.01 mEq/L (P<.001 vs
baseline)
Mild hyperkalemia: 0.65 mEq/L
Moderate to severe hyperkalemia:
1.23 mEq/L
Continued on next page
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TABLE 3. Continued
Study name; design (duration)

Patient population

Study treatment

Primary efﬁcacy outcomes

Withdrawal stage: patiromer (at
same dosage) or placebo
(Kþ 3.8-5.1 mEq/L)

Withdrawal stage:
Median change in Kþ to wk 4:
0 mEq/L with patiromer
þ0.72 mEq/L with placebo
P<.001 vs placebo

SZC
ENERGIZE; phase 2,
randomized, double-blind,
placebo-controlled (24 h)88

Emergency department
patients with serum Kþ
5.8 mEq/L; N¼70

SZC 10 g (3 doses in 10 h) or
placebo (þ insulin þ glucose)

LS mean change in serum Kþ at 4 h:
0.41 mEq/L with SZC
0.27 mEq/L with placebo
LS mean difference vs placebo:
0.13 mEq/L (95% CI 0.44 to
0.17 mEq/L)

Phase 3, 2-stage, randomized,
double-blind, placebocontrolled (14 d)89

Patients with hyperkalemia
(Kþ 5.0-6.5 mEq/L);
N¼754

Correction phase:
SZC 1.25, 2.5, 5, or 10 g or
placebo TID for 48 h

Correction phase:
Exponential rate of change in mean
serum Kþ at 48 h:
0.11% with SZC 1.25 g
0.16% with SZC 2.5 g
0.21% with SZC 5 g
0.30% with SZC 10 g
0.09% with placebo
P<.001 vs placebo for 3 highest doses

Maintenance phase:
SZC (same dose) or placebo
QD (Kþ 3.5-4.9 mEq/L)
for 14 d

Maintenance phase:
Exponential rate of change in mean
serum Kþ:
þ0.14% per hour with
SZC 10 g þ1.04% per hour with
placebo
P<.001
þ0.09% per hour with SZC 5 g þ0.47%
per hour with placebo
P¼.008

Initial phase (open-label):
SZC 10 g TID for 48 h

Initial phase (open-label):
Mean change in serum Kþ over 48 h:
1.1 mEq/L; P<.001 vs baseline

Maintenance phase (double-blind):
SZC 5, 10, or 15 g or placebo QD
for 28 d (Kþ 3.5-5.0 mEq/L)

Maintenance phase (double-blind):
Mean serum Kþ during days 8-29:
4.8 mEq/L with SZC 5 g QD
4.5 mEq/L with SZC 10 g QD
4.4 mEq/L with SZC 15 g QD
5.1 mEq/L with placebo
P<.001 vs placebo for each dose

SZC 10 g QD, titrated in 5-g
amounts to maintain Kþ
3.5-5.0 mEq/L (min, 5 g QD;
max, 15 g QD)

93% of patients achieved mean serum
Kþ 5.1 mEq/L across days 8-337

Correction phase (open-label):
SZC 10 g TID for 48 h

Correction phase (open-label):
Mean change in serum Kþ over 48 h:

HARMONIZE; phase 3, 2stage, randomized,
double-blind, placebocontrolled (28 d)90

HARMONIZE-OLE; phase
3, open-label (11 mo)91

HARMONIZE-Global;
phase 3, randomized,

Outpatients with hyperkalemia (Kþ 5.1 mEq/
L); N¼258

Patients from
HARMONIZE with Kþ
3.5-6.2 mEq/L; N¼123

Continued on next page
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TABLE 3. Continued
Study name; design (duration)

Patient population

Study treatment

1.28 mEq/L; P<.001 vs baseline

Outpatients with
hyperkalemia (Kþ 5.1
mEq/L); N¼267

double-blind, placebocontrolled (28 d)92

ZS-005; phase 3, 2-stage,
open-label (12 mo)93

Outpatients with
hyperkalemia (Kþ 5.1
mEq/L); N¼751

Patients with ESRD on
hemodialysis with
hyperkalemiaf; N¼196

DIALIZE; phase 3b,
randomized, double-blind,
placebo-controlled
(4 wk)94

Primary efﬁcacy outcomes

Maintenance phase (doubleblind):
SZC 5 or 10 g or placebo QD
for 28 d (Kþ 3.5-5.0 mEq/L)

Maintenance phase (double-blind):
Mean serum Kþ during days 8-29:
4.8 mEq/L with SZC 5 g QD
4.4 mEq/L with SZC 10 g QD
5.3 mEq/L with placebo
P<.001 vs placebo for each dose

Correction phase:
SZC 10 g TID for 24-72 h

Correction phase:
78% of patients had serum Kþ 3.5-5.0
mEq/L at 72 h

Maintenance phase:
SZC 5 g QDe

Maintenance phase:
88% of patients had serum
Kþ <5.1 mEq/L over 3-12 mo

SZC 5, 10, or 15 g or placebo
QD on nondialysis days
for 4 wk

Maintenance of predialysis serum Kþ
4.0-5.0 mEq/L during 3 of 4 hemodialysis sessions after long interdialytic
interval without requiring rescue
therapy:
41% with SZC
1% with placebo
P<.001 vs placebo

AMBER ¼ Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease; AMETHYST-DN ¼ Patiromer in the Treatment of
Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy; BID ¼ twice daily; CKD ¼ chronic kidney disease; DIALIZE ¼ A Study to Test Whether ZS
(Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients; DKD ¼ diabetic kidney disease; ENERGIZE ¼ A
Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K 5.8; ESRD ¼ end-stage renal
disease; HARMONIZE ¼ Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance; HARMONIZE-OLE ¼ HARMONIZE open-label extension; HF ¼ heart
failure; Kþ ¼ potassium; LS ¼ least squares; max ¼ maximum; min ¼ minimum; OPAL-HK ¼ A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efﬁcacy and Safety of
Patiromer for the Treatment of Hyperkalemia; PEARL-HF ¼ Evaluation of Patiromer in Heart Failure Patients; QD ¼ once daily; RAASi ¼ renin-angiotensin-aldosterone
system inhibitor; SOC ¼ standard of care; SPS ¼ sodium polystyrene sulfonate; SZC ¼ sodium zirconium cyclosilicate; TID ¼ three times daily.
b
Spironolactone dosage increased to 50 mg/d after 2 weeks in patients with serum Kþ >3.5 to 5.1 mEq/L.
c
Patiromer was titrated to achieve and maintain serum Kþ 5.0 mEq/L.
d
Spironolactone dosage increased to 50 mg/d after 3 weeks in patients with systolic blood pressure 120 mm Hg and serum Kþ 5.1 mEq/L.
e
SZC was titrated to maintain serum Kþ 3.5-5.0 mEq/L.
f
Deﬁned as predialysis serum Kþ >5.4 mEq/L after the long interdialytic interval and predialysis serum Kþ >5.0 mEq/L after 1 short interdialytic interval.
a

separated by 3 or more hours.78 Of note, the
release of sodium from SPS during Kþ
exchange may potentially increase sodium
and volume load. Sodium polystyrene sulfonate should be used with caution in patients
with congestive HF, severe hypertension,
edema, or decreased kidney function who
may not tolerate increased sodium loads.12,78
Patiromer Sorbitex Calcium. The efﬁcacy of
patiromer was established in randomized,
placebo-controlled, phase 2 and 3 trials of
Mayo Clin Proc. n XXX 2020;nn(n):1-19
www.mayoclinicproceedings.org

n

patients with hyperkalemia, including those
with CKD and HF, and/or receiving RAASis
(Table 3). In a pilot study of emergency
department patients with ESRD and serum Kþ
levels of 6.0 mEq/L or higher, single-dose
administration of patiromer, 25.2 g, in addition to standard of care effectively reduced
serum Kþ concentrations over 6 hours.83 In
patients with chronic hyperkalemia, patiromer,
4.2 to 16.8 g twice daily, provided signiﬁcant
dose-dependent reductions in serum Kþ levels
by 0.2 to 1.0 mEq/L over 4 weeks84,85,87 and
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effectively maintained normokalemia (Kþ
levels of 3.8 to 5.1 mEq/L) for a further 4
weeks.87 In patients with advanced CKD and
resistant hypertension, signiﬁcantly more patients continued spironolactone, 25 to 50 mg
once daily, while receiving patiromer, 8.4 g
once daily, vs placebo for 12 weeks.86 Among
patients with diabetes and CKD, including
those with HF receiving RAASis, normokalemia was maintained with patiromer therapy for
up to 12 months.105 In a real-world study of
patients undergoing long-term hemodialysis,
serum Kþ concentrations were signiﬁcantly
reduced following initiation of patiromer over
three 30-day periods, and the proportion of
patients with serum Kþ levels of 6.0 mEq/L or
higher decreased from approximately 50%
before patiromer initiation to 22% at 90 days
after patiromer initiaton.106
Oral patiromer contains a calciumsorbitol counterion that exchanges calcium
for Kþ as it passes through the colon.77
Similar to SPS, patiromer is a polymer that
is nonselective for Kþ and may also bind
magnesium and small amounts of sodium.77,107 The time to onset of action
with patiromer is approximately 7 hours.108
Patiromer administration should also be
separated from other oral medications by 3
or more hours because of the potential for
binding with patiromer.77
No serious AEs have been associated
with patiromer therapy in randomized trials.
The most common AEs include gastrointestinal events (constipation, diarrhea, nausea/
vomiting, abdominal discomfort, and ﬂatulence) and electrolyte disturbances (hypokalemia and hypomagnesemia).12,77,81 Because
patiromer exchanges calcium for Kþ in the
colon, theoretically it may also increase the
risk of hypercalcemia.12 Although rare, cases
of patiromer-induced hypercalcemia have
been reported,109,110 suggesting that it may
be an underreported AE that clinicians
should be aware of when initiating patiromer
therapy. Currently, there are no real-world
safety data for patiromer.
Sodium Zirconium Cyclosilicate. Sodium
zirconium cyclosilicate (SZC) is the most
recently approved Kþ-binding agent, with its
14
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efﬁcacy and safety established in phase 2 and
3 clinical trials of patients with hyperkalemia
including those with CKD, HF, and/or diabetes
or those receiving RAASis (Table 3).88-94 In a
study of emergency department patients with
serum Kþ concentrations of 5.8 mEq/L or
higher, SZC therapy (up to three 10-g doses
within 10 hours) added to insulin plus glucose
provided reductions in mean serum Kþ levels
of 0.72 mEq/L within 2 hours.88 In studies of
patients with chronic hyperkalemia, 3-timesdaily SZC signiﬁcantly reduced serum Kþ
concentrations within 48 hours, and a oncedaily 5- or 10-g SZC dose effectively maintained normokalemia over 14 to 28
days.89,90,92 Signiﬁcant reductions in serum
Kþ levels were observed within 1 hour of a
single SZC 10-g dose in the overall patient
populations89,90,92 and in those with severe
hyperkalemia (6.0 mEq/L).111 The efﬁcacy
and safety of SZC over 12 months have also
been documented.91,93 In the DIALIZE (A
Study to Test Whether ZS [Sodium Zirconium
Cyclosilicate] Can Reduce the Incidence of
Increased Blood Potassium Levels Among
Dialized Patients) study of patients with ESRD
and persistent hyperkalemia, once-daily SZC
on nondialysis days effectively maintained
normal predialysis serum Kþ levels over 8
weeks.94 Sustained increases in serum bicarbonate have been observed with SZC,112 which
may provide an added beneﬁt for patients with
metabolic acidosis.
Unlike SPS and patiromer, SZC is nonpolymeric with high selectivity for Kþ and ammonium ions (1.25-fold higher afﬁnity for Kþ
than ammonium) in exchange for hydrogen
and sodium throughout the gastrointestinal
tract.79 Sodium zirconium cyclosilicate binds
monovalent cations (Kþ) as opposed to divalent cations (eg, calcium and magnesium).113
Because SZC may affect absorption of other
oral medications with pH-dependent solubility
due to a transient increase in gastric pH, SZC
administration should be separated from these
medications by 2 or more hours.79
Sodium zirconium cyclosilicate has not
been associated with any serious AEs in randomized trials. The most common AEs were
hypokalemia and a dose-dependent increase
in edema.89,90,93 Because SZC was only
XXX 2020;nn(n):1-19
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recently launched in US and other markets,
postmarketing safety data are currently very
limited.
Hyperkalemia Education
The National Kidney Foundation recommends improvements in patient awareness
of hyperkalemia.114 These actions include using educational tools to facilitate communication about hyperkalemia (eg, https://www.
kidney.org/atoz/content/what-hyperkalemia)
and encouraging nurse practitioners, physicians, physician assistants, pharmacists, and
dietitians to proactively engage patients in
dialogue about the associated risk of hyperkalemia and provide ongoing dietary and other
lifestyle information relevant to patients with
increased hyperkalemia risk.114
Educational initiatives and campaigns are
needed to improve patient awareness of hyperkalemia risk and its potentially life-threatening
consequences, including awareness that hyperkalemia is often asymptomatic and that routine
Kþ monitoring is important. Allied health care
professional involvement in patient education
may help to increase awareness of the hyperkalemia risk associated with RAASi and other
medications. Health care practitioners should
be involved in patient education regarding
hyperkalemia to promote shared care responsibility and treatment planning.
CONCLUSION
Critical unmet needs exist regarding effective
hyperkalemia management, including classiﬁcation and monitoring for hyperkalemia, reinitiation and maximization of RAASi therapy,
and use of Kþ-binding agents. Hyperkalemia
incidence may be higher than previously reported, and the risks associated with acute
and chronic hyperkalemia may be reduced
through vigilant individualized serum Kþ
monitoring. With the availability of newer
Kþ-binding agents, clinicians have increased
need for education on their use as well as to
increase patient awareness about the signs,
symptoms, and risks of hyperkalemia. Newer
Kþ-binding agents may enable the optimization of RAASi therapy in more patients with
hyperkalemia.
Mayo Clin Proc. n XXX 2020;nn(n):1-19
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